Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | SDCBP | O00560 | 1/20 | 0.38 |
| ▸ | SDC2 | P34741 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 8/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887439 | 0.88 | SDCBP (0.46) | PARP1PARP10CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18086772 | 0.84 | SDCBP (0.45) | PARP1TDP1L3MBTL1PARP10HTR2A | |
| SCHEMBL21784003 | 0.81 | GRM5 (0.38) | GRM5MEN1KMT2A | |
| SCHEMBL18067757 | 0.81 | HPGD (0.42) | GRM5LMNAGFER | |
| SCHEMBL4316519 | 0.79 | DRD2 (0.49) | PARP1L3MBTL1CYP1A2CYP3A4HTR2A | |
| SCHEMBL29407570 | 0.79 | MEN1 (0.53) | PARP1TDP1L3MBTL1PARP10TYMS | |
| SCHEMBL2016126 | 0.79 | MEN1 (0.53) | PARP1TDP1L3MBTL1PARP10TYMS | |
| SCHEMBL6924020 | 0.77 | GRM5 (0.47) | TDP1L3MBTL1HTR2AHTR2CHTR2B | |
| SCHEMBL29896985 | 0.77 | GRM5 (0.47) | TDP1L3MBTL1HTR2AHTR2CHTR2B | |
| SCHEMBL19887444 | 0.76 | AHR (0.41) | HTR2CGRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220235087-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10738070-B2 | Mannose-derived antagonists of FimH useful for treating disease | FIMBRION THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190106451-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | CLIMATE LLC | 2019-04-11 | — | — | US | disclosed |
| EP-3432892-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | Fimbrion Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3426260-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | Fimbrion Therapeutics, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017165619-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017156508-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156508-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009723-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885TDP1 4121/4885L3MBTL1 2553/4885 |
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885TDP1 4121/4885L3MBTL1 2553/4885 |
| US-20220235087-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885TDP1 4121/4885L3MBTL1 2553/4885 |
| US-10738070-B2 | Mannose-derived antagonists of FimH useful for treating disease | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885TDP1 4121/4885L3MBTL1 2553/4885 |
| US-20190106451-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885TDP1 4121/4885L3MBTL1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.